(ACB) Aurora Cannabis Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ACB) Aurora Cannabis Inc. Complete Analysis Pack
See the Bigger Picture
This Aurora Cannabis Inc. 4P's Marketing Mix Analysis explains the company’s Product, Price, Place, and Promotion strategies and what they mean for market positioning and sales; it’s designed for marketing research, strategy, and benchmarking. The page contains a real preview/sample of the analysis so you can evaluate style and content—purchase the full version to get the complete ready-to-use report.
Product
Dried cannabis strains
Aurora Cannabis Inc. keeps dried cannabis as a core product for medical patients and wholesale buyers, with strains sold under Aurora, San Rafael '71, MedReleaf, CanniMed, and Whistler. In fiscal 2025, Aurora reported net revenue of C$343.7 million, showing this format still drives the business. The wide strain mix helps the Company serve different patient needs while supporting steady supply.
Cannabis oils and capsules
Aurora Cannabis Inc. sells cannabis oils and capsules for medical patients, giving them measured dosing and a non-smoke option. In FY2025, the Company kept medical cannabis as a core revenue stream, with these formats widening choice beyond dried flower and supporting more tailored use cases.
Topical and oral formulations
Aurora Cannabis Inc. is building medical cannabis products in oral and topical forms, while also developing edible and inhalable options, so patients can choose the delivery method that fits their needs. In fiscal 2025, Aurora reported net revenue of about C$343 million, showing this product mix supports a real commercial base. That broader formulation strategy also helps the Company serve different treatment routines, from fast-acting inhalables to longer-lasting oral and topical products.
Vaporizers and accessories
Aurora Cannabis Inc.'s vaporizers and accessories line, including grinders, herb mills, and secure containers, supports cannabis use and storage while lifting basket size beyond flower sales. In fiscal 2025, Aurora reported net revenue of C$314.4 million, and these add-on items help capture more spend per order.
- Boosts basket size and convenience
- Supports use and secure storage
- Adds low-cost, repeatable margin
Patient support and testing services
Aurora Cannabis Inc. broadens Patient support and testing services beyond product sales with CanvasRX counseling centers, patient support, and analytical testing; it also adds design, engineering, and construction work for cannabis facilities. In FY2025, this service layer helped diversify a business that still depends on cannabis gross revenue, which was CA$343.4 million.
- CanvasRX adds patient-facing support.
- Testing services support quality control.
- Facility services widen the mix beyond goods.
Aurora’s Medical Cannabis Mix Keeps FY2025 Sales Anchored
Aurora Cannabis Inc. centers Product on medical cannabis, led by dried flower plus oils and capsules, with brands like Aurora, San Rafael 71, MedReleaf, CanniMed, and Whistler. FY2025 net revenue was C$343.7 million, so the mix still anchors sales. The range gives patients choice on dose, format, and use.
| Product | FY2025 data | Role |
|---|---|---|
| Dried flower | C$343.7M net revenue | Core revenue driver |
| Oils and capsules | Medical mix | Measured dosing |
| Brands | Aurora, San Rafael 71, MedReleaf | Broader patient reach |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of Aurora Cannabis Inc.’s product, pricing, distribution, and promotion strategy.
Editable Excel File
Condenses Aurora Cannabis’s 4Ps into a quick, at-a-glance view that eases strategy review and team alignment.
Reference Sources
Consolidates reputable industry reports, government data, and company filings to speed due diligence and verify Aurora Cannabis assumptions.
Place
Canada-wide market access
Canada-wide market access is Aurora Cannabis Inc.'s main home base, with products sold through Health Canada-regulated channels to medical patients across the country. Canada had about 41 million people in 2025, giving Aurora a large, familiar market for brand presence and repeat access. The company’s Canadian medical channel stays central to patient reach, trust, and refill demand.
International distribution
Aurora Cannabis Inc. sells medical cannabis in international markets, including Europe and Australia, so it is not tied to Canada alone. In fiscal 2025, Aurora reported net revenue of C$343.7 million, and its international reach helps widen that base. This access matters because medical cannabis demand keeps growing outside Canada, especially in regulated export markets. It also reduces reliance on one market and supports longer-term growth.
Wholesale channels
Aurora Cannabis Inc. uses wholesale channels to move product through partner networks into wider medical and commercial markets. This helps the Company reach more buyers without building every sales touchpoint itself. Wholesale is key for volume movement and market coverage.
Retail and patient access channels
Aurora Cannabis Inc. uses retail-facing and patient-facing channels to make cannabis easier to access, especially through CanvasRX centers, which support counseling and community outreach. These touchpoints help patients find products faster and get guidance on use, which strengthens service quality and repeat access.
- CanvasRX centers support patient counseling.
- Retail channels widen end-user access.
- Outreach improves education and service.
Edmonton corporate base
Aurora Cannabis Inc.'s main office is in Edmonton, Canada, which centralizes management and oversight for its global medical cannabis business. In fiscal 2025, Aurora reported net revenue of about C$330 million and operated across Canada and Europe, so Edmonton acts as the control hub for that network. That base supports coordination with production and distribution sites.
- Edmonton: core management hub
- Supports global production and distribution
- Fits Aurora's C$330 million FY2025 scale
Aurora Cannabis: Canada Core, Global Reach
Aurora Cannabis Inc. uses Canada as its core place market, with Health Canada-regulated medical access and a 41 million-population base in 2025. It also sells in Europe and Australia, so its reach is not Canada-only. Wholesale partners and CanvasRX centers widen access and support patient guidance.
| Place channel | Role |
|---|---|
| Canada | Core medical market |
| Europe/Australia | International reach |
| Wholesale | Broader distribution |
| CanvasRX | Patient support |
What You See Is What You Get
Aurora Cannabis Inc. Reference Sources
The preview shown here is the actual Aurora Cannabis 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Multi-brand portfolio
Aurora Cannabis Inc. promotes a 10-brand portfolio, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. That spread lets Company Name target different patient needs and price points, from value to premium. It also strengthens brand recall across medical cannabis channels in Canada and abroad.
Medical patient education
Aurora Cannabis uses patient education as a core promotion tool, since its medical business depends on informed demand. With medical cannabis sold in 20+ countries, the company’s support helps patients choose formats, understand dosing, and match products to their needs. That matters in a category where trust and product knowledge can drive repeat use.
CanvasRX outreach
CanvasRX outreach helps Aurora Cannabis Inc. turn clinics into counseling and community touchpoints, not just sales points. In a market where Aurora reported C$65.0 million in net revenue in fiscal 2025 Q3, this direct patient setting can lift trust, awareness, and repeat engagement while supporting premium brand recall.
Wholesale and partner communication
Aurora Cannabis Inc. promotes through wholesale and partner communication, using B2B trade ties to place products with distributors, retail channels, and healthcare buyers. In fiscal 2025, that channel-led model supported C$343.7 million in net revenue and helped the Company keep selling in a tightly regulated market where partner trust matters most.
- Focuses on wholesale and retail partners
- Uses B2B outreach for healthcare buyers
- Fits cannabis compliance and traceability rules
R and D credibility
Aurora Cannabis Inc. uses research and development, breeding programs, and analytical testing to back its quality claims. In FY2025, net revenue was about C$344 million, and that scale helps make its science-led medical story more credible. The message is simple: better testing and genetics support higher trust.
- Breeding supports product consistency
- Testing backs quality claims
- R&D strengthens medical credibility
Aurora Cannabis Drives Growth Across 20+ Countries
Aurora Cannabis Inc. promotes through patient education, clinic outreach, and partner communication, which fits its regulated medical market. In fiscal 2025, net revenue was C$343.7 million, and Q3 fiscal 2025 net revenue was C$65.0 million. Its 10-brand portfolio supports both premium and value positioning across 20+ countries.
| Promotion lever | Data point |
|---|---|
| Brands | 10 |
| Markets | 20+ countries |
| FY2025 net revenue | C$343.7M |
| Q3 FY2025 net revenue | C$65.0M |
Price
Regulated market pricing
Aurora Cannabis Inc. sets prices inside regulated cannabis markets, so local rules and taxes matter more than pure demand. In Canada, excise duty is the greater of C$1 per gram or 10% of the selling price, and provincial markups add more pressure. That keeps pricing less flexible, but it lets Aurora tailor prices by market and channel.
Tiered brand pricing
Aurora Cannabis Inc. uses tiered brand pricing by pairing premium names with value-oriented labels, so it can sell to both cost-sensitive and premium buyers. In fiscal 2025, Aurora reported about C$343 million in net revenue, showing it can support multiple price points across its portfolio. That mix helps protect volume while keeping higher-priced brands available for customers who want stronger positioning.
Format-based pricing
Aurora Cannabis uses format-based pricing, so dried flower, oils, capsules, topicals, and accessories are priced differently based on production and packaging costs. In fiscal 2025, Aurora reported net revenue of C$343.2 million, showing demand across multiple formats. This tiered pricing creates multiple entry points for customers, from lower-cost dried cannabis to higher-priced specialty delivery forms.
Medical affordability focus
Aurora Cannabis Inc.’s medical focus supports patient affordability, especially in a repeat-buy market. In fiscal 2025, Aurora generated about C$343 million in net revenue, so value lines matter for retention. Daily Special helps keep entry prices low while protecting volume in medical channels.
- Medical buyers often repurchase regularly
- Value brands support lower price points
- Repeat demand makes affordability critical
Channel-specific pricing
Aurora Cannabis Inc. can price differently in wholesale and retail, and that matters because customer pricing shifts by route, volume, and province. In Canada, cannabis excise duty is the higher of C$1 per gram or 10% of the sale price, so jurisdiction can change the final shelf price fast.
That lets Aurora Cannabis Inc. protect margin on larger wholesale lots while staying competitive in retail channels. It also helps match price to market access and local demand across 13 provinces and territories.
- Wholesale and retail can carry different prices.
- Province rules affect final customer cost.
- Volume discounts support margin control.
- Channel pricing helps fit demand.
Aurora Cannabis Balances Regulated Pricing With Tiered Brand Power
Aurora Cannabis Inc. keeps price under tight regulation, with Canada excise duty at the higher of C$1 per gram or 10% of selling price, plus provincial markups. In fiscal 2025, net revenue was C$343.2 million, showing it can support both value and premium pricing. Tiered brands and format-based pricing help it fit medical and adult-use demand.
| Price driver | Fiscal 2025 / current data |
|---|---|
| Net revenue | C$343.2 million |
| Canada excise duty | C$1/gram or 10% |
| Pricing mix | Tiered, format-based |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.